LABS vs. RX, CRDL, HLS, TGOD, NINE, SUGR, WMD, MDP, HEXO, and VIR
Should you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include BioSyent (RX), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), SugarBud Craft Growers (SUGR), WeedMD (WMD), Medexus Pharmaceuticals (MDP), HEXO (HEXO), and Viridium Pacific Group (VIR). These companies are all part of the "drug manufacturers - specialty & generic" industry.
MediPharm Labs vs.
BioSyent (CVE:RX) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
BioSyent has higher earnings, but lower revenue than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioSyent had 1 more articles in the media than MediPharm Labs. MarketBeat recorded 1 mentions for BioSyent and 0 mentions for MediPharm Labs. BioSyent's average media sentiment score of 1.05 beat MediPharm Labs' score of 0.00 indicating that BioSyent is being referred to more favorably in the media.
BioSyent has a net margin of 20.60% compared to MediPharm Labs' net margin of -30.56%. BioSyent's return on equity of 20.01% beat MediPharm Labs' return on equity.
BioSyent received 69 more outperform votes than MediPharm Labs when rated by MarketBeat users. Likewise, 66.20% of users gave BioSyent an outperform vote while only 65.79% of users gave MediPharm Labs an outperform vote.
1.4% of BioSyent shares are held by institutional investors. Comparatively, 0.7% of MediPharm Labs shares are held by institutional investors. 33.7% of BioSyent shares are held by company insiders. Comparatively, 4.5% of MediPharm Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioSyent has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, MediPharm Labs has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
Summary
BioSyent beats MediPharm Labs on 14 of the 15 factors compared between the two stocks.
Get MediPharm Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediPharm Labs Competitors List
Related Companies and Tools
This page (TSE:LABS) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy LABS Stock Free LABS Stock Alerts